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Abstract 
In this study, we show that during normal rat pregnancy, there is a gestational stage-dependent decrease in androgen receptor 
(AR) abundance in the gravid uterus and that this is correlated with the differential expression of endometrial receptivity 
and decidualization genes during early and mid-gestation. In contrast, exposure to 5α-dihydrotestosterone (DHT) and insulin 
(INS) or DHT alone significantly increased AR protein levels in the uterus in association with the aberrant expression of 
endometrial receptivity and decidualization genes, as well as disrupted implantation. Next, we assessed the functional rel-
evance of the androgen-AR axis in the uterus for reproductive outcomes by treating normal pregnant rats and pregnant rats 
exposed to DHT and INS with the anti-androgen flutamide. We found that AR blockage using flutamide largely attenuated 
the DHT and INS-induced maternal endocrine, metabolic, and fertility impairments in pregnant rats in association with 
suppressed induction of uterine AR protein abundance and androgen-regulated response protein and normalized expression 
of several endometrial receptivity and decidualization genes. Further, blockade of AR normalized the expression of the 
mitochondrial biogenesis marker Nrf1 and the mitochondrial functional proteins Complexes I and II, VDAC, and PHB1. 
However, flutamide treatment did not rescue the compromised mitochondrial structure resulting from co-exposure to DHT 
and INS. These results demonstrate that functional AR protein is an important factor for gravid uterine function. Impairments 
in the uterine androgen-AR axis are accompanied by decreased endometrial receptivity, decidualization, and mitochondrial 
dysfunction, which might contribute to abnormal implantation in pregnant PCOS patients with compromised pregnancy 
outcomes and subfertility.
Key messages 
• The proper regulation of uterine androgen receptor (AR) 
contributes to anormal pregnancy process, whereas the 
aberrant regulation of uterine AR mightbe linked to 
polycystic ovary syndrome (PCOS)-induced pregnancy-
relatedcomplications.
• In the current study, we found that during normal rat 
pregnancy there isa stage-dependent decrease in AR 
abundance in the gravid uterus and that thisis correlated 
with the differential expression of the endometrial recep-
tivityand decidualization genes Spp1, Prl, Igfbp1,and 
Hbegf.
• Pregnant rats exposed to 5α-dihydrotestosterone (DHT) 
and insulin (INS)or to DHT alone show elevated uterine 
AR protein abundance and implantationfailure related to 
the aberrant expression of genes involved in endometrial-
receptivity and decidualization in early to mid-gestation.
• Treatment with the anti-androgen flutamide, starting 
frompre-implantation, effectively prevents DHT + INS-
induced defects in endometrialreceptivity and deciduali-
zation gene expression, restores uterine mitochondrial-
homeostasis, and increases the pregnancy rate and the 
numbers of viablefetuses.
• This study adds to our understanding of the mechanisms 
underlying poorpregnancy outcomes in PCOS patients 
and the possible therapeutic use ofanti-androgens, includ-
ing flutamide, after spontaneous conception.
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Introduction
Polycystic ovary syndrome (PCOS) is one of the most common 
gynecological disorders associated with fertility difficulties, 
and it affects 5–25% of all adolescent and reproductive-aged 
women across multiple geographic ancestries and ethnici-
ties [1–3]. It has a multifactorial etiology and is character-
ized by reproductive dysfunction accompanied by metabolic 
abnormalities, and women with PCOS have an increased risk 
for pregnancy-related complications [4–6]. The etiologies of 
PCOS are not fully understood, but several possible hypoth-
eses for the uterine manifestations observed in PCOS patients 
have been postulated to involve hyperandrogenism (andro-
gen excess) together with obesity-related insulin resistance 
[6–8]. The majority of women with PCOS have attempted or 
achieved pregnancy. However, data from clinical observational 
studies indicate that early pregnancy loss, both in spontane-
ous and in vitro fertilization-induced conceptions, is more 
common in PCOS patients than in healthy women [9, 10]. 
Moreover, the incidence of pregnancy loss and infertility in 
PCOS patients with androgen excess is positively associated 
with the incidence of pregnancy loss in PCOS patients with 
insulin resistance [11]. Moreover, Dokras et al. previously 
reported that hyperinsulinemic states are positively correlated 
with ovarian androgen levels in women during pregnancy [12]. 
Therefore, in addition to their separate roles, the coordinated 
roles of maternal hyperandrogenism and insulin resistance may 
also account for the early pregnancy loss in PCOS patients. 
In addition, infertile PCOS patients may experience psycho-
logical distresses such as anxiety and depression [13]. These 
circumstances emphasize the need for a better understanding 
of the causes of PCOS-induced pregnancy loss and infertility.
The appropriate regulation of the endometrium, a 
dynamic mucosa layer of the uterus, is essential for embryo 
implantation during pregnancy [14–16]. The uterine endo-
metrium consists of luminal and glandular epithelial cells, 
stromal fibroblasts, and vascular and immune cells that 
are involved in ovarian steroid hormone (17β-estradiol 
and progesterone)-orchestrated structural and signaling 
events, including endometrial receptivity, implantation, 
and decidualization [14, 17]. Moreover, extensive evidence 
from gene expression studies and transgenic mouse models 
indicates that aberrant alterations of endometrial epithe-
lia and/or stroma-specific molecules and factors, as well 
as their interactions, can disturb these pregnancy-related 
processes, which subsequently might lead to implantation 
failure and fetal loss [15, 16, 18]. The myometrium is able 
to synthesize androgens such as testosterone and nonaro-
matizable 5α-dihydrotestosterone (DHT) during normal 
pregnancy [19]. However, whether and how the activity of 
the myometrium, the thickest layer of the uterus, contrib-
utes to successful embryo implantation is far from clear.
A recent Swedish nationwide register-based cohort study 
indicated that early initiation of anti-androgen treatment 
is correlated with a greater chance of childbirth in PCOS 
patients after spontaneous conception [20]. However, the 
underlying mechanisms behind anti-androgen actions in 
pregnant PCOS patients were unclear. Common opinion 
holds that the concerted actions of androgens are mostly, but 
not completely, mediated through binding to nuclear andro-
gen receptor (AR), which belongs to a superfamily of ligand-
induced transcription factors [21]. An increasing body of 
pre-clinical and clinical evidence supports the idea that the 
androgen-AR axis plays an important role in normal uter-
ine function for both cycling and pregnant females [22, 23]. 
For example, in humans, circulating androgen levels peak 
around the time of ovulation, and AR mRNA and protein are 
predominantly localized to stromal cells in the endometrium 
and are regulated throughout the menstrual cycle [23, 24]. 
Findings from clinical observational studies indicate that 
circulating androgen levels are higher in PCOS patients than 
non-PCOS women during pregnancy [25, 26], suggesting a 
further role for androgens in females in the disease state. Of 
note, treatment with the anti-androgen flutamide decreases 
clinical hyperandrogenism and improves menstrual cycle 
regularity and ovulation in affected women [27]. In addi-
tion, there are perturbations in endometrial AR expression 
that parallel the impairment of endometrial function and the 
subsequent progression of the hallmarks of PCOS [7, 24, 
28]. However, whether an aberrant or dysfunctional andro-
gen-AR axis is a cause or consequence of the pathogenesis 
of PCOS remains speculative.
In rats, we have recently demonstrated that mid-gesta-
tional exposure to DHT and insulin (INS) produces a PCOS-
like phenotype (i.e., hyperandrogenism and insulin resist-
ance) with increased fetal loss [29, 30]. We show that the 
dysregulation of implantation and decidualization-related 
gene expression and ferroptosis is involved in gravid uterine 
defects in pregnant rats co-exposed to DHT and INS [29, 
31]. Given that mitochondrial defects might be an interest-
ing additional mechanism that could potentially contribute 
to the pathophysiology of PCOS [32], we and others have 
reported that mitochondrial dysfunction-triggered oxida-
tive stress is significantly increased in PCOS patients who 
have recurrent miscarriage [33, 34], as well as in PCOS-like 
rodents [29, 30, 35, 36]. Further, in-utero exposure to fluta-
mide significantly alters the mitochondrial-dependent apop-
totic program in rat AR-positive testicular Sertoli and germ 
cells [37, 38], although no evidence for this is reported in 
female reproductive tissues. Taken together, these previous 
studies support the hypothesis that gravid uterine dysfunc-
tion can induce PCOS-induced pregnancy-related compli-
cations via AR-dependent regulation of implantation and 
mitochondrial functioning.
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In the present study, we evaluated the spatial and tempo-
ral cellular expression patterns of the AR protein in relation 
to endometrial receptivity and decidualization-related gene 
expression in rats exposed to DHT and/or INS during gesta-
tion. To determine the functional relevance of the androgen-
AR axis in the gravid uterus, we exposed normal pregnant rats 
and pregnant rats co-exposed to DHT and INS to flutamide 
and assessed changes in uterine morphology, endometrial 
receptivity and decidualization-related gene expression, and 
mitochondrial morphology and functional markers, as well 
as maternal metabolism and fertility. Our findings emphasize 
the complexity of the relationship between AR protein abun-
dance and endometrial receptivity and decidualization-related 
gene expression and suggest that impairments in the uterine 
androgen-AR axis are accompanied by decreased endometrial 
receptivity, decidualization, and mitochondrial function. More-
over, these impairments likely contribute to the subfertility and 
compromised pregnancy outcomes seen in PCOS patients.
Materials and methods
Materials, animal care, and experimental protocols
All experiments complied with the ARRIVE guidelines 2.0 
(updated guidelines for reporting animal research) [39]. 
Adult Sprague–Dawley female (n = 72) and male (n = 36) 
rats were obtained from the Laboratory Animal Centre 
of Harbin Medical University, Harbin, China. On arrival, 
all animals were maintained in an environmentally con-
trolled and pathogen-free barrier facility on a standard 12 h 
light/12 h dark cycle at 22 ± 2 °C and 55–65% humidity and 
with free access to normal diet and water. All rats were used 
at 70 days of age. Before any experiment was performed, 
female rats were allowed to acclimatize for a minimum of 
7 days and then were monitored daily by vaginal lavage 
to determine the stage of the estrous cycle [40, 41]. Only 
rats shown to be in regular estrous cycles were selected for 
mating experiments. Successful mating was confirmed by 
microscopic analysis of vaginal smears for the presence of 
sperm and the appearance of a vaginal plug (designated as 
gestational day (GD) 0.5). Mated females were randomly 
assigned to the different treatment groups after excluding 
for other confounding factors such as body condition and 
weight as described previously [29, 30].
Experimental design
Experiment 1 For the time-course studies, pregnant rats 
were randomly assigned to be intraperitoneally injected 
daily from GD 0.5 with DHT (1.66 mg/kg/day, suspended 
in sesame oil, Sigma-Aldrich, St. Louis, MO, USA) and/or 
INS (6.0 IU/day, human recombinant INS diluted in sterile 
saline, Eli Lilly Pharmaceuticals, Giza, Egypt) or an equal 
volume of saline and sesame oil as controls. This generated 
the following four study groups (n = 8/group) for comparison: 
control, DHT + INS, DHT, and INS. The treatment regime 
is shown in Fig. 1A, and the rationale for the doses of DHT 
and INS has been previously described [29–31, 36, 41]. 
Chronic exposure of pregnant rats to DHT and INS results 
in hyperandrogenism and insulin resistance [29, 30], which 
is equivalent to that found in PCOS patients [25, 26, 42, 43]. 
All animals were exposed to isoflurane (2% in a 1:1 mixture 
of oxygen or air, RWD Life Science Co., Shenzhen, China) 
followed by exsanguination. Rats were sacrificed on GD 4.5, 
7.5, 10.5, and 14.5. The reason for choosing GD 4.5 to GD 
14.5 was the necessity to follow the physiological and cel-
lular events such as endometrial receptivity, decidualization, 
and embryo implantation that occur in rodents during early 
and mid-gestation [18]. If implanted embryos were found, 
a stereomicroscope was used to separate fetal and placen-
tal tissues from the uterine wall. Uterine tissues were dis-
sected, weighed, and immediately frozen in liquid nitrogen 
and stored at − 70 °C for quantitative real-time PCR (qPCR) 
and Western blot analyses or fixed for morphological and 
immunohistochemical analyses.
Experiment 2 For pharmacological studies, the anti-androgen 
flutamide (25 mg/kg/day, suspended in 100 µl sesame oil, 
F-9397, Sigma-Aldrich) [44, 45] or vehicle (100 µl sesame 
oil) was intraperitoneally injected daily from GD 0.5 in con-
trol and DHT + INS-exposed pregnant rats (n = 20/group). The 
flutamide dose was specifically chosen as it has been found 
to effectively improve DHT-induced defects in ovarian mor-
phology and to restore reproductive cycles in a PCOS-like 
rodent model [46]. The oral glucose tolerance test (OGTT) 
was assessed in pregnant rats on GD 13.5, and animals were 
allowed to recover overnight before blood collection. On GD 
14.5, all rats were exposed to isoflurane (2% in a 1:1 mixture 
of oxygen or air, RWD Life Science Co.), followed by exsan-
guination. Trunk blood was collected directly from the heart 
and maintained at room temperature for 1 h before isolation 
of serum. Following sacrifice, the uterus was dissected, the 
number of implanted embryos was recorded, and the fetal and 
placental tissues were separated from the uterine wall under 
a stereomicroscope. Further, uterine tissues were dissected, 
weighed, and immediately frozen in liquid nitrogen and stored 
at −70 °C for qPCR and Western blot analyses or fixed for 
morphological and immunochemical analyses.
OGTT 
Glucose tolerance was assessed in pregnant rats on GD 
13.5 using an OGTT as described previously [29, 30]. 
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Briefly, rats were fasted for 10 h and blood glucose con-
centrations were determined at 0, 30, 60, 90, and 120 min 
after D-glucose administration (3 g/kg body weight in 
saline, oral). Glucose concentrations were measured using 
a hand-held glucometer from blood sampled from the tail 
vein.
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RNA isolation and qPCR
The isolation and quantification of the RNA and the 
qPCR assays were performed as previously described 
[31, 47]. The PCR amplifications were performed with 
SYBR green qPCR master mix (#K0252, Thermo Sci-
entific, Rockford, IL). Total RNA was prepared from 
the frozen whole uterine tissues, and single-stranded 
cDNA was synthesized from each sample (2 μg) with 
M-MLV reverse transcriptase (#0,000,113,467, Pro-
mega Corporation, Fitchburg, WI) and RNase inhibitor 
(40 U) (#00,314,959, Thermo Scientific). cDNA (1 μl) 
was added to a reaction master mix (10 μl) containing 
2 × SYBR green qPCR reaction mix (Thermo Scien-
tific) and gene-specific primers (5 μM of forward and 
reverse primers). All reactions were performed at least 
twice, and each reaction included a nontemplate con-
trol. Specific sample sizes are denoted in the figure 
legends. Several housekeeping genes, including Gapdh, 
Actb (β-actin), and L19, were tested before analysis. 
However, only Gapdh and Actb were stably expressed 
between the groups and thus used as the reference gene 
for our analysis. Fold changes in mRNA expression were 
calculated by the ΔΔCT method using Gapdh and Actb 
as the endogenous controls, and the results are expressed 
as fold changes after normalizing to the controls. The 
qPCR primers used in this study are listed in Supple-
mental Table 1. All sets of primers were validated for 
qPCR prior to analysis. This involved determining that 
the efficiency of amplification using a standard curve of 
cDNA was above 85% and not different from the Gapdh 
and Actb reference genes, and there were no nonspecific 
PCR products seen in a melting curve analysis immedi-
ately after the amplification or in parallel reactions with 
un-transcribed RNA or in reactions without templates 
(the negative controls).
Protein isolation and Western blot analysis
The extraction of total protein and Western blot analy-
sis was conducted with standard protocols as previously 
described [31, 48]. Uterine tissue proteins were isolated 
by homogenization in radioimmunoprecipitation assay 
buffer (Sigma-Aldrich) supplemented with cOmplete 
Mini protease inhibitor cocktail tablets (Roche Diagnos-
tics, Mannheim, Germany) and PhosSTOP phosphatase 
inhibitor cocktail tablets (Roche Diagnostics). After deter-
mining the total protein concentration by Bradford protein 
assay (Thermo Fisher Scientific), equal amounts (30 μg) 
of protein were resolved on 4–20% TGX stain-free gels 
(Bio-Rad Laboratories GmbH, Munich, Germany) and 
transferred onto polyvinylidene fluoride membranes. The 
membranes were probed with different primary antibodies 
(Supplemental Table 2) in 0.01 M Tris-buffered saline sup-
plemented with Tween 20 containing 5% w/v nonfat dry 
milk followed by anti-rabbit IgG horseradish peroxidase 
(HRP)-conjugated goat (A0545) or anti-mouse IgG HRP-
conjugated goat (A2304) secondary antibody (1:1000 dilu-
tion, Sigma-Aldrich). Signal was detected using the Super-
Signal West Dura Extended Duration Substrate (Thermo 
Fisher Scientific) and captured using a ChemiDoc MP 
Imaging System (Bio-Rad). For each Western blot, ultra-
violet activation of the Criterion stain-free gel was used to 
assess total protein loading for each sample. Band densi-
tometry was performed using Image Laboratory (Version 
5.0, Bio-Rad), and the intensity of each protein band was 
normalized to the total protein in the individual sample for 
calculating protein abundance data. Due to the number of 
samples per group, multiple gels were run per group. For 
quantification and to ensure standardization across blots, 
the abundance of the target protein was normalized to the 
mean value for the control group on the blot, and then all 
of the normalized values were compared in order to assess 
the effects of the treatments. This ensured the accurate 
comparison of protein abundance across groups with the 
single tissue sample.
Histological examination and immunohistochemical 
staining
Histological processing and immunohistochemistry were 
performed according to previously described methods [47, 
48]. The 4% formaldehyde-fixed uterine tissues were sub-
jected to paraffin embedding and sectioned at 5 μm. Tissue 
sections were stained with hematoxylin and eosin (H&E) 
or with immunohistochemistry. After heat-induced antigen 
retrieval by pressure cooking in citrate buffer (pH 6), endog-
enous peroxidase activity was quenched by incubation with 
3% hydrogen peroxide in phosphate-buffered saline (PBS) 
Fig. 1  Exposure to DHT or INS alone or in combination alters body 
weight, embryo or fetal number, and implantation-related gene 
expression in rats during pregnancy. Schematic of the experimental 
design A. Comparison of body weight and embryo or fetal number 
in pregnant rats treated with DHT and/or INS (B, n = 8/group). The 
fertility index is the percentage of matings that resulted in pregnancy. 
In all plots the data are presented as means ± SEM. aP < 0.05, Control 
(vehicle) group vs. DHT + INS group; bP < 0.01, Control group vs. 
DHT group; cP < 0.05, DHT + INS group vs. INS group; dP < 0.05, 
DHT group vs. INS group. *P < 0.05, ***P < 0.001. Time-dependent 
changes in implantation-related gene expression C. After remov-
ing the embryos/fetuses and placenta, uterine tissues from pregnant 
rats treated with vehicle, DHT + INS, DHT, or INS were used for 
analyzing genes for uterine receptivity and decidualization by qPCR 
(n = 4–6/group). In all plots, data are presented as means ± SEM (vs. 
Control GD 4.5 values). Statistical tests are described in the “Mate-
rials and methods” section, and differences between the groups are 
reported as *P < 0.05, ** P < 0.01, and ***P < 0.001
◂
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for 10 min, and then nonspecific binding was blocked with 
10% normal goat serum for 1 h at room temperature. Tissue 
sections were incubated with the primary antibody against 
AR (Supplemental Table 2) overnight at 4 °C in a humidified 
chamber. Afterward, slides were stained using the avidin-
biotinylated-peroxidase ABC kit followed by a 5-min treat-
ment with 3,3′-diaminobenzidine (DAB, SK-4100, Vector 
Laboratories). The optimal concentration of anti-AR anti-
body (1:200) was determined in initial experiments, and 
background settings were adjusted from the examination 
of negative control specimens prepared using a rabbit IgG 
antibody (Supplemental Fig. 1.1–1.6). The anti-AR antibody 
was also initially characterized for specificity using human 
prostatic tissues and cell lines and in rat testis tissues by 
Western blotting and immunofluorescence analyses accord-
ing to the manufacturer’s instructions (https:// www. abcam. 
com/ andro gen- recep tor- antib ody- epr15 352- ab133 273. html), 
and no specific immunoreactivity was detected in neighbor-
ing tissue sections (Supplemental Figs. 2.6 and 4.7–4.8). 
Stained samples were observed and imaged on a Nikon 
E-1000 microscope (Japan) under bright-field optics and 
photomicrographed using Easy Image 1 (Bergström Instru-
ment AB, Sweden). All images were taken with precisely the 
same parameters for all experimental groups.
TEM
Transmission electron microscopy (TEM) was performed 
according to published reports [30, 31]. Briefly, fresh uter-
ine tissues were fixed in 2.5% glutaraldehyde in phosphate-
buffered saline (PBS, pH 7.2–7.4) for 1 h at room temper-
ature and further rinsed with 0.1 M PBS three times for 
15 min each. The tissues then underwent permeation and 
dehydration, and samples were finally embedded in Epon 
epoxy resin. The 50–60 nm sections were post-stained with 
3% uranyl acetate and lead citrate and were viewed using a 
transmission electron microscope (H-7650, Hitachi, Japan) 
equipped with an electron imaging spectrometer. Image col-
lection and parameter settings were identical for each of the 
different tissues/regions analyzed.
Measurement of biochemical parameters
The concentrations of serum hormones (total testosterone 
(T), androstenedione (A4), DHT, dehydroepiandrosterone 
(DHEA), sex hormone-binding globulin (SHBG), pro-
gesterone (P4), 17β-estradiol (E2), and fasting INS) were 
quantified using chemiluminescence (Beckman Coulter, 
Inc., CA, and Abbott Laboratories, IL). The reproducibil-
ity (intra/inter-assay coefficients of variation) of rat T, A4, 
DHT, DHEA, SHBG, P4, E2, and INS were 6.2%/6.6%, 
6.7%/6.9%, 6.2%/6.7%, 6.3%/6.6%, 6.4%/6.8%, 6.4%/6.6%, 
6.5%/6.8%, and 6.3%/6.6%, respectively.
Statistical analysis
No statistical methods were used to pre-determine the sample 
size. Statistical analyses were performed using SPSS ver-
sion 24.0 for Windows (SPSS Inc., Chicago, IL). The normal 
distribution of the data was tested with the Shapiro–Wilk 
test. For the time-course studies, normally distributed data 
were analyzed by two-way ANOVA (including the factors 
of GD and hormonal treatment) followed by pairwise Tukey 
post hoc tests. For the pharmacological studies using the AR 
antagonist flutamide, normally distributed data were analyzed 
by one-way ANOVA followed by Tukey post hoc tests. Data 
that were not normally distributed were tested for statistical 
significance between groups with the Kruskal–Wallis test. 
Data are presented as means ± standard error of the mean 
(SEM), and the sample size (n) is listed in the figure legends 
and indicates the number of pregnant rats in each experiment. 
All P-values less than 0.05 were considered statistically sig-
nificant. The main effects of GD and/or hormonal treatment 
are referred to as PGD, Ptreatment, and PGD:treatment, respectively. 
Pearson’s correlation coefficient was used to examine the 
strength of the associations between AR protein expression 
and the mRNA levels of genes contributing to endometrial 
receptivity and decidualization in the gravid uterus from con-
trol pregnant rats from GD 4.5 to GD 14.5.
Results
Regulation of endometrial receptivity 
and decidualization‑related gene expression 
in pregnant rats in response to different hormonal 
treatments
As shown in Fig. 1B, age-matched DHT + INS-exposed 
and DHT-exposed pregnant rats were lighter than controls 
and INS-exposed pregnant rats at GD 14.5. We found that 
from GD 7.5 to GD 14.5, the fertility index was the same 
between controls and INS-exposed pregnant rats. However, 
DHT + INS-exposed and DHT-exposed pregnant rats had 
no apparent pregnancies compared to control and INS-
exposed pregnant rats. Although maternal exposure to INS 
significantly reduced the embryo number at GD 7.5 com-
pared to controls, there were no embryos or fetuses found 
in DHT + INS or DHT-exposed pregnant rats from GD 7.5 
to GD 14.5. We therefore determined whether early and 
mid-gestational exposure to DHT and/or INS affects endo-
metrial receptivity and decidualization-related gene expres-
sion in the gravid uterus (Fig. 1C). There were significant 
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interactions between different GDs and treatments in deter-
mining the overall gene expression of Lif, Nr2f2, Ptch, 
Spp1, Prl, Hoxa10, and Il11 (PGD < 0.05, Ptreatment < 0.05, 
PGD:treatment < 0.05). Additionally, GD exerted a significant 
effect on Pc6, Igfbp1, Hoxa11, and Hbegf mRNA expres-
sion (PGD < 0.05, PGD:treatment < 0.05), whereas the hormonal 
treatment had a significant effect on Pgr mRNA expression 
(Ptreatment < 0.001, PGD:treatment < 0.001).
At GD 4.5, all hormonal treatments reduced Prl mRNA 
expression compared to controls but did not affect Nr2f2, 
Ptch, Spp1, Igfbp1, Il11, or Hbegf mRNA expression 
(Fig. 1C). Although the Hoxa11 mRNA level was lower 
in DHT + INS-exposed and DHT-exposed pregnant rats 
compared to controls at GD 4.5, we found that Pc6 and 
Hoxa10 mRNAs were increased in DHT + INS-exposed 
pregnant rats compared to controls and to DHT-exposed 
and INS-exposed pregnant rats. At GD 7.5, five of the 
measured mRNAs (Nr2f2, Ptch, Pgr, Hoxa11, and Hbegf) 
showed no changes in any of the treatment groups, 
whereas Spp1 and Prl mRNAs were decreased in preg-
nant rats exposed to DHT and/or INS compared to con-
trols (Fig. 1C). At the same time, Lif, Pc6, and Hoxa10 
mRNAs were decreased and Igfbp1 mRNA expression was 
increased in DHT + INS-exposed pregnant rats compared 
to control pregnant rats. At both GD 10.5 and GD 14.5, Lif 
and Spp1 mRNA expression remained reduced, but Nr2f2 
and Ptch mRNAs were increased in DHT + INS-exposed 
and DHT-exposed pregnant rats compared to controls 
(Fig. 1C). We did not find any significant differences in 
Prl, Igfbp1, or Hoxa10 mRNA expression in response to 
the hormonal treatments at GD 10.5, but these three genes 
were decreased in pregnant rats exposed to DHT and/or 
INS compared to control pregnant rats at GD 14.5. In addi-
tion, maternal exposure to DHT alone or together with INS 
decreased Pc6, Hoxa11, and Il11 mRNA expression at GD 
10.5, while Pgr and Hbegf mRNAs were increased at this 
GD. At GD 14.5, we also found increased Pgr and Hbegf 
mRNAs and decreased Hoxa11 mRNA in DHT + INS-
exposed pregnant rats compared to control pregnant rats. 
These findings suggest that there are stage-dependent 
alterations in endometrial receptivity and decidualization-
related gene expression in the gravid uterus during normal 
pregnancy. Moreover, these can be influenced by maternal 
exposure to DHT and INS and are related to implantation 
failure during gestation.
Distinctive patterns of uterine AR expression 
and localization in pregnant rats in response 
to different hormonal treatments
We then sought to determine whether gestational-age 
dependent endometrial receptivity and decidualization-
related gene expression might be related to AR expression 
in the gravid uterus and if aberrant uterine AR expression 
is occurring in pregnant rats exposed to DHT and/or INS. 
Using Western blotting (Fig. 2), we found that exposure to 
DHT + INS and to DHT alone significantly affected uterine 
AR abundance from GD 4.5 to GD 14.5 (Ptreatment < 0.001, 
PGD:treatment = 0.023). In particular, uterine AR abundance 
was increased in DHT-exposed pregnant rats compared to 
controls at all GDs. However, a similar increase in AR abun-
dance was only observed in DHT + INS-exposed pregnant 
rats compared to controls at GD 7.5 and GD 14.5. There was 
no significant difference in AR abundance between control 
and INS-exposed pregnant rats at any GD (Fig. 2).
Pearson correlation analysis showed that in control preg-
nant rats, uterine AR abundance was significantly correlated 
with Spp1, Prl, Igfbp1, and Hbegf mRNA expression and 
with vimentin and α-SMA protein abundance from GD 4.5 
to GD 14.5 (Table 1). Western blotting showed that the abun-
dance of cytokeratin, which is highly abundant in endome-
trial epithelial cells, was increased in DHT + INS-exposed 
and DHT-exposed pregnant rats compared to controls from 
GD 7.5 to GD 14.5 (Ptreatment < 0.001, PGD:treatment = 0.016), 
while the abundance of vimentin, which is mainly in endo-
metrial stromal cells (PGD = 0.001, PGD:treatment = 0.003), 
and α-smooth muscle actin, which is mainly in uter-
ine myometrial cells (PGD = 0.002, Ptreatment < 0.001, 
PGD:treatment = 0.002), were increased in DHT + INS-exposed 
and DHT-exposed pregnant rats compared to controls at GD 
14.5 (Fig. 2).
According to the GD-dependent structural changes in the 
rat uterus [49, 50], we found that from GD 4.5 to GD 14.5, the 
development of the gravid uterus was histo-morphologically 
normal in controls (Fig. 3A1–A4, and Suppl Figs. 2–4) and 
was similar in INS-exposed pregnant rats (Fig. 3D1–D4). In 
contrast, we found that compared to control and INS-exposed 
pregnant rats, DHT + INS-exposed and DHT-exposed pregnant 
rats contained endometrial and myometrial compartments at 
all stages. With increasing GD, the gravid uterine diameters 
(middle zone — endometrial compartment) were decreased 
by exposure to DHT + INS (Fig. 3B1–B4) and to DHT alone 
(Fig. 3C1–C4). Consistent with studies on human samples [24, 
51, 52], immunohistochemical studies in control pregnant rats 
showed that AR nuclear immunoreactivity was detected in 
decidual stromal cells and myometrial smooth muscle cells, 
with lower expression in luminal and gradual epithelial cells 
at GD 4.5 (Fig. 3A5), GD 7.5 (Fig. 3A6 and Suppl Fig. 2), 
and GD 10.5 (Fig. 3A7, and Suppl Fig. 3). In addition, the 
reduction in AR immunoreactivity in the gravid uterus during 
gestation was found in the mesometrial decidua and triangle 
compartments in control pregnant rats (Fig. 3A8). A similar 
loss of cellular AR immunoreactivity during gestation was also 
seen in the gravid uterus of INS-exposed pregnant rats (except 
that decidual stromal cells showed higher immunoreactiv-
ity at GD 4.5) (Fig. 3D5–D8). Regardless of the GD studied, 
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strong AR immunoreactivity was observed in stromal cells 
in the DHT + INS-exposed and DHT-exposed gravid uterus 
(Fig. 3B5–B8 and C5–C8, upper and middle rows). In addition, 
immunostaining for AR was absent, or very sparse, in luminal 
and glandular epithelial cells at all GDs in the DHT + INS-
exposed and DHT-exposed rats (Fig. 3B5–B8 and C5–C8, 
upper and middle rows). Despite the stepwise variation of AR 
immunoreactivities when plotted against GD, AR was distrib-
uted homogeneously in smooth muscle cells across the myo-
metrium in DHT + INS-exposed and DHT-exposed pregnant 
rats (Fig. 3B5–B8 and C5–C8, bottom rows). These findings 
indicate that the stage-dependent and androgen-specific regula-
tion of uterine AR protein abundance is associated with changes 
in endometrial functional gene expression.
Flutamide reversed metabolic and endocrine 
abnormalities and partially restored fertility 
in DHT + INS‑exposed pregnant rats
Our next goal was to evaluate whether the inhibition of andro-
gen-AR activation with flutamide could rescue the gravid 
uterine defects and infertility induced by combined exposure 
to DHT and INS (which mimic the typical PCOS features). 
Flutamide treatment did not affect body weight, uterine 
weight, fertility index, or fetal number in control pregnant 
rats at GD 14.5 (Fig. 4A–D). However, flutamide treatment 
increased the body weight of DHT + INS-exposed pregnant 
rats whether they did or did not have fetuses (Fig. 4A). Flu-
tamide also increased uterine weight in DHT + INS-exposed 
pregnant rats (with fetuses), although this value was still 
significantly lower than control pregnant rats (Fig. 4B). The 
improved uterine weight in flutamide-treated DHT + INS-
exposed pregnant rats (with fetuses) reflected a 70% increase 
in pregnancy rate and a similar fetal number compared to 
control pregnant rats (Fig. 4C, D). In line with the hyperan-
drogenic conditions, circulating total T and A4 concentra-
tions were increased in DHT + INS-exposed pregnant rats 
compared to controls (Fig. 4E, F). Treatment with flutamide 
increased P4 concentration in both control and DHT + INS-
exposed pregnant rats (with fetuses) but did not affect P4 
concentration in DHT + INS-exposed pregnant rats (without 
fetuses) (Fig. 4J). There was no effect of flutamide on DHT, 
DHEA, SHBG, or E2 concentrations in control pregnant rats, 
but SHBG was reduced by flutamide in DHT + INS-exposed 
pregnant rats (with fetuses) (Fig. 4G-K). Furthermore, con-
trol and flutamide-treated DHT + INS-exposed pregnant 
rats (with fetuses) were significantly more glucose tolerant 
compared to DHT + INS-exposed pregnant rats without flu-
tamide treatment (Fig. 4L, M). Of note, even with flutamide 
treatment, DHT + INS-exposed pregnant rats with fetuses 
exhibited a greater increase in glucose tolerance compared 
to DHT + INS-exposed pregnant rats without fetuses (Fig. 4L, 
M). These data suggest that flutamide treatment partially 
improves fertility and metabolic aberrations in pregnant rats 
with hyperandrogenism and insulin resistance.
Impact of flutamide on uterine morphology, 
endometrial receptivity and decidualization‑related 
gene expression, and AR and androgen‑regulated 
protein expression
We observed that control and DHT + INS-exposed preg-
nant rats (with fetuses) treated with flutamide showed 
Table 1  Pearson correlation coefficients for the relation of AR protein 
abundance, implantation-related genes, and uterine cell marker pro-
tein expression in the gravid uterus of control pregnant rats
n = 5–6/GD
AR androgen receptor, Lif leukemia inhibitory factor, Nr2f2 nuclear 
receptor subfamily 2 group F member 2, Pc6 protein convertase 5/6, 
Ptch patched, Spp1 osteopontin/secreted phosphoprotein 1, Prl prol-
actin, Igfbp1 insulin-like growth factor binding protein 1, Pgr proges-
terone receptor, Hoxa10 homeobox A10, Il11 interleukin-11, Hbegf 
heparin-binding EGF-like growth factor, α-SMA α-smooth muscle 
actin
AR Coefficient, r p value
Implantation-related genes




Spp1  −0.46 0.04
Prl 0.56 0.01
Igfbp1  −0.54 0.02
Pgr 0.38 0.08
Hoxa10  −0.16 0.49
Hoxa11  −0.25 0.28
Il11 0.10 0.66
Hbegf 0.46 0.04
Uterine cell marker proteins
pan-Cytokeratin 0.03 0.88
Vimentin 0.69  < 0.01
α-SMA 0.59  < 0.01
Fig. 2  Differential regulation of AR protein in uteri collected from 
pregnant rats exposed to DHT and/or INS from GD 4.5 to GD 14.5. 
Time-dependent regulation of AR protein abundance in the pregnant 
uterus. After removing the embryos/fetuses and placenta, the uterine 
tissues from pregnant rats treated with control (vehicle), DHT + INS, 
DHT, or INS were used for analyzing AR and uterine cell marker 
proteins (cytokeratin, vimentin, and α-smooth muscle actin) by West-
ern blotting. In all plots, the relative mean protein abundance ± SEM 
(vs. Control GD 4.5 values, n = 5–6/group) was measured by West-
ern blotting with total proteins serving as loading controls. Statistical 
tests are described in the “Materials and methods” section, and differ-
ences between the groups are reported as *P < 0.05, **P < 0.01, and 
***P < 0.001. The size representation in kilodaltons (kDa), as deter-
mined by a molecular weight ladder, is shown to the right
◂
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similar uterine histo-morphology as untreated control rats 
(Fig. 5A, B-D). However, in line with our previous obser-
vation (Fig. 3B4), the uteruses from DHT + INS-exposed 
pregnant rats without flutamide treatment showed both endo-
metrial and myometrial compartments (Fig. 5C). Addition-
ally, we found that the numbers and infiltration of immune 
cells into the luminal and glandular epithelia and the stroma 
were increased in DHT + INS-exposed pregnant rats without 
flutamide treatment (Fig. 5C). These histological features 
were also observed in flutamide-treated DHT + INS-exposed 
pregnant rats that had no fetuses (Supplemental Fig. 5).
In agreement with previous results (Fig. 1C), there was 
significant dysregulation of several endometrial recep-
tivity and decidualization-related genes (i.e., Lif, Nr2f2, 
Fig. 3  Localization of the AR protein in uteri collected from pregnant 
rats exposed to DHT and/or INS from GD 4.5 to GD 14.5. Histologi-
cal appearance of gravid uteri using hematoxylin and eosin (H&E) 
staining (A1–A4, B1–B4, C1–C4, and D1–D4) and AR localization 
by immunohistochemistry (A5–A8, B5–B8, C5–C8, and D5–D8) in 
pregnant rats treated with vehicle A, DHT + INS B, DHT C, or INS 
D. Images are representative of eight tissue replicates. GD, gesta-
tional day; DHT, 5α-dihydrotestosterone; INS, insulin; En, endome-
trium; Cm, circular myometrium; Lm, longitudinal myometrium; 
Le, luminal epithelial cells; Ge, glandular epithelial cells; Str, stro-
mal cells; E, embryo; PDZ, primary decidual zone; MT, mesome-
trial triangle; MD, mesometrial decidua; P, placental disc. Scale bars 
(100 μm) are indicated in the photomicrographs
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Ptch, Spp1, Prl, Igfbp1, Pgr, Hoxa11, and Hbegf) between 
control and DHT + INS-exposed pregnant rats (Fig. 5E). 
Among these genes, treatment with flutamide decreased 
Lif and Il11 mRNAs in control pregnant rats (Fig. 5E). 
However, we found that flutamide treatment decreased 
Nr2f2, Ptch, Pgr, and Hbegf mRNAs and increased Spp1, 
Igfbp1, and Hoxa11 mRNAs in DHT + INS-exposed preg-
nant rats (with fetuses) (Fig. 5E). Because  p21WAF1/CIP1 is 
an androgen-regulated response protein [53], and because 
the mitochondrial marker proteins (VDAC and PHB1) are 
dysregulated in the placentas of pregnant rats co-exposed 
to DHT and INS [30], we sought to determine whether 
flutamide could regulate the expression of these proteins 
in the pregnant rat uterus. We observed significantly 
increased protein abundance of AR,  p21WAF1/CIP1, VDAC, 
and PHB1 in DHT + INS-exposed pregnant rats compared 
to control rats (Fig. 5F). Although no differences in AR, 
 p21WAF1/CIP1, VDAC, or PHB1 protein abundance were 
seen with flutamide treatment in control rats, we found 
that flutamide significantly decreased the abundance of 
Fig. 4  Chronic treatment with flutamide induces changes in hor-
mones and metabolites in control and DHT + INS-exposed pregnant 
rats at GD 14.5. Comparison of body weight A, uterine weight B, 
fertility index C, fetal number D, serum total T E, A4 F, DHT G, 
DHEA H, SHBG I, P4 J, E2 K, blood glucose concentrations dur-
ing OGTT L, and area under the curve (AUC) for glucose M  in 
pregnant rats treated with and without DHT and INS [n = 10/group, 
except for the DHT + INS + flutamide group (with fetuses, n = 7) 
and the DHT + INS + flutamide (without fetuses) group (n = 3)]. The 
fertility index is the percentage of matings that resulted in preg-
nancy. AUC was calculated by the formula [0.5 × (BG0 + BG30)/
2 + 0.5 × (BG30 + BG60)/2 + 0.5 × (BG60 + BG90)/2 + 0.5 × (BG
90 + BG120)/2], where the BG terms are the blood glucose levels 
at 0  min, 30  min, 60  min, 90  min, and 120  min. aP < 0.05, control 
(vehicle) group vs. DHT + INS group; bP < 0.05, control group vs. 
DHT + INS + flutamide (no fetuses) group; cP < 0.05, DHT + INS 
group vs. DHT + INS + flutamide (with fetuses) group; dP < 0.05, 
DHT + INS + flutamide group vs. DHT + INS + flutamide (with-
out fetuses) group. In all plots, data are presented as means ± SEM. 
Statistical tests are described in the “Materials and methods” sec-
tion, and differences between the groups are reported as *P < 0.05, 
**P < 0.01, and ***P < 0.001
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these proteins in DHT + INS-exposed pregnant rats (with 
fetuses) compared to DHT + INS-exposed pregnant rats 
without flutamide treatment (Fig. 5F). These values were 
similar to those seen in untreated control pregnant rats. 
These findings indicate that the beneficial effect of fluta-
mide in DHT + INS-exposed pregnant rats is mediated by 
suppression of AR signaling in association with changes 
in implantation-related gene expression in the uterus dur-
ing pregnancy.
Flutamide partially protected 
against the development of uterine stromal cell 
mitochondrial impairment in DHT + INS‑exposed 
pregnant rats
Due to the changes in gravid uterine mitochondrial function 
and homeostasis in response to hyperandrogenism and insu-
lin resistance [29], we asked whether flutamide might res-
cue the mitochondrial morphological and functional defects 
Fig. 5  Effects of flutamide on uterine morphology, implantation-
related gene expression, and AR,  p21WAF1/CIP1, and mitochondrial 
marker protein expression in control and DHT + INS-exposed preg-
nant rats at GD 14.5. Histological analysis by H&E staining in vehi-
cle control A, B and DHT + INS-exposed C, D pregnant rats treated 
with flutamide B, D. The yellow arrowheads indicate infiltrated 
immune cells in the endometrial gland. Images are representative of 
7–10 tissue replicates. Ut, uterus; P, placenta; MT, mesometrial tri-
angle; MD, mesometrial decidua; M, myometrium; En, endometrium; 
G, gland. Scale bars (100 μm) are indicated in the photomicrographs. 
After removing the embryos/fetuses and placentas, uterine tissues 
from control and DHT + INS-treated pregnant rats treated with flu-
tamide were used for analyzing uterine receptivity and decidualiza-
tion genes by qPCR (F, n = 5–7/group), and the relative abundance 
of AR,  p21WAF1/CIP1, VDAC, and PHB1 proteins was determined by 
Western blotting (G, 5–6/group). The size representation in kDa, as 
determined by a molecular weight ladder, is shown to the right. In all 
plots, data are presented as means ± SEM (vs. control vehicle values). 
Statistical tests are described in the “Materials and methods” sec-
tion, and differences between the groups are reported as *P < 0.05, 
**P < 0.01, and ***P < 0.001
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in the gravid uterus induced by DHT + INS exposure. As 
shown in Fig. 6A, while flutamide treatment did not signifi-
cantly impact Tfam, Pgc1a, or Nrf1 mRNA expression in 
control pregnant rats, it significantly increased uterine Nrf1 
mRNA expression in DHT + INS-exposed pregnant rats with 
fetuses. Although flutamide treatment did not affect Tfam or 
Pgc1a mRNA in DHT + INS-exposed pregnant rats, those 
values were now similar to untreated control pregnant rats 
(Fig. 6A). The mitochondrial oxidative phosphorylation sys-
tem is composed of five multi-subunit enzymatic complexes 
[54], and using Western blotting, we found that flutamide 
treatment decreased Complex III and increased Complex IV 
protein levels in control pregnant rats (Fig. 6B). Complex 
I and II abundances were increased in DHT + INS-exposed 
pregnant rats, and these effects were abolished by flutamide 
treatment (in the DHT + INS with fetuses group) (Fig. 6B). 
Furthermore, TEM analysis showed that compared to con-
trols with normal mitochondrial ultrastructure (Fig. 6C1), 
DHT + INS-exposed pregnant rats exhibited swollen stro-
mal mitochondria with collapsed and poorly defined tubu-
lar cristae (Fig. 6C3). Despite the observation of shrunken/
fewer swollen mitochondria in the decidual stromal cells, 
less electron-dense mitochondria with missing and disorgan-
ized cristae were still detected in the DHT + INS-exposed 
pregnant rats treated with flutamide (Fig. 6C4). These mito-
chondrial ultrastructural changes were also evident in control 
rats treated with flutamide (Fig. 6C2).
Pregnant rats exposed to DHT and INS or DHT alone 
exhibit ovarian alterations in contrast to flutamide 
treatment
The impact of DHT and INS on ovarian weight in pregnant 
rats exposed to DHT and/or INS from GD 4.5 to GD 14.5 
was determined (Suppl Fig. 6). We did not find any signifi-
cant differences for any of the experimental groups from GD 
4.5 to GD 10.5; however, we found that on GD 14.5, the 
ovarian weight was significantly decreased in DHT + INS- 
and DHT-exposed pregnant rats compared to control and 
INS-exposed pregnant rats. The corpus lutea (CL) produce 
several hormones for successful implantation and pregnancy 
maintenance. Histological analyses and CL counting further 
revealed that in the ovaries of DHT + INS-exposed preg-
nant rats, the proportion of the CL number (n < 5) per ovary 
was increased to 55.6% compared to control rats (11.1%). 
After flutamide treatment, the decreased proportion of the 
CL number (n < 5) per ovary was evident in DHT + INS-
exposed pregnant rats (28.6%), similar to that observed in 
control rats (30.0%) (Suppl Fig. 7A, B). There results sug-
gest that impaired ovarian function might lead to uterine 
AR-mediated abnormal implantation in pregnant rats with 
hyperandrogenism.
Discussion
There are elevated circulating androgen levels in PCOS 
patients also during pregnancy [4, 5, 25, 26], and PCOS 
patients have an increased incidence of adverse reproductive 
outcomes, including pregnancy loss, compared to healthy 
women [4–6]. Androgen responsiveness is controlled 
primarily by AR expression [21], which has been implicated 
in endometrial dysfunction in non-pregnant PCOS patients 
[24, 28]. However, major knowledge gaps remain regarding 
whether AR is regulated in the gravid uterus during normal 
pregnancy establishment, and if so to what extent the effects 
of aberrant uterine AR lead to PCOS-induced adverse 
pregnancy outcomes. In this study, we show that AR is 
differentially expressed in all cell types of the gravid uterus 
during early and mid-gestation, and we show that the stage-
dependent decrease in AR protein abundance is correlated 
with Spp1, Prl, Igfbp1, and Hbegf mRNA expression. This 
suggests that AR signaling has a pivotal role in embryo 
implantation. Our previous study in which we exposed rats 
to DHT and/or INS between GD 7.5 and GD 14.5 (mid- 
gestation) showed that the expression of genes that are 
involved in endometrial receptivity and decidualization 
were aberrant in the gravid uterus [29]. The present study 
shows that the AR protein abundance is consistently 
higher in pregnant rats exposed to DHT and INS together 
or to DHT alone compared to control pregnant rats and 
to pregnant rats exposed to INS from GD 0.5 to GD 14.5. 
Moreover, we show that elevated AR protein abundance 
is accompanied by a lack of implantation likely due to 
the aberrant expression of genes involved in endometrial 
receptivity and decidualization in pregnant rats exposed 
to DHT and INS or to DHT alone, whereas exposure to 
INS alone affected these parameters to a lower degree. In 
both human and rodent studies [6], in vivo exposure and 
in vitro stimulation of androgens not only are associated 
with, but also directly regulate, the endometrial receptivity 
and decidualization-related gene expression, and they 
influence cell oxidative stress, proliferation, and apoptosis. 
Previous studies demonstrated that female AR knockout 
mice exhibited smaller uteri with an abnormal estrous cycle, 
impaired placental development, and reduced fertility over 
time [55, 56]. Based upon the aforementioned evidence, 
it was speculated that the causality of androgen-induced 
uterine dysfunction and subfertility might be the result of 
two opposite extremes, namely AR overexpression and AR 
knockdown. However, the idea of AR-related subfertility 
has been challenged by the observations that a mouse model 
with an in-frame deletion of exon 3 of the Ar gene [57] 
presents with decreased ovarian weight and ovulation rate, 
increased unhealthy antral follicle number and ovarian T 
level, and reduced litter size [57, 58] as well as abnormal 
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Fig. 6  Effects of flutamide on mitochondrial transcriptional activa-
tion, uterine oxidative phosphorylation (OXPHOS) protein expres-
sion, and mitochondrial morphology in control and DHT + INS-
exposed pregnant rats at GD 14.5. After removing the embryos/
fetuses and placentas, uterine tissues from control and DHT + INS-
exposed pregnant rats treated with flutamide were used for analyzing 
mRNA levels of Tfam, Pgc1a, and Nrf1 by qPCR (A, n = 5–7/group), 
and the relative protein abundance of  O2-dependent mitochondrial 
OXPHOS subunits was determined by Western blotting (B, Com-
plexes I–V, 5–6/group). The size representation in kDa, as determined 
by a molecular weight ladder, is shown to the right. In all plots, data 
are presented as means ± SEM (vs. Control vehicle values). Statistical 
tests are described in the “Materials and methods” section, and dif-
ferences between the groups are reported as * P < 0.05, ** P < 0.01, 
and *** P < 0.001. Uterine ultrastructural analysis by TEM in control 
(C1–C2) and DHT + INS-treated (C3–C4) pregnant rats treated with 
flutamide (C2 and C4). Images are representative of two tissues per 
group, and enhanced magnifications are shown in the lower panel of 
each photomicrograph. DB, decidual basalis; Epi, epithelial cells; Str, 
stromal cells. Scale bars (2 μm) are indicated in the photomicrographs
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neuroendocrine function [58]. According to this mouse 
model, the lack of non-functional AR (which involves the 
ligand-induced nuclear localization of a transcriptionally 
inactive AR protein) does not affect uterine-related 
reproductive capabilities (e.g., damaged implanted embryo 
viability, and perturbed pup survival and gestational length) 
[58]. These results suggest that uterine AR signaling 
might not be essential for normal pregnancy and fertility. 
However, similar to our pregnant PCOS-like rats, these AR 
knockout mice exhibit a significant decrease in ovarian 
weight and in CL and implantation site numbers, as well as 
reduced uterine weight and reduced endometrial area [58]. 
Because our present study documents the complexity of the 
disturbances to the androgen-AR signaling axis that result 
in impaired endometrial receptivity and decidualization 
processes, future investigation should determine whether 
elevated androgen levels, increased AR distribution 
and activity, and/or impaired androgen-AR signaling 
mechanisms have an impact on uterine-related implantation 
failure and infertility using uterine tissue/cell-specific AR 
knockout mice.
A significant strength of this study is the mechanistic find-
ings from chronic administration of flutamide for treating 
infertility in pregnant rats under conditions of hyperandro-
genism and insulin resistance (resulting from co-exposure 
to DHT and INS). The biological effects of flutamide are 
mediated through competitively inhibiting the binding of 
androgens to the AR [59], and at the molecular and func-
tional levels, our data demonstrate that treatment with fluta-
mide from pre-implantation, through implantation, to post-
implantation suppresses the increased AR and  p21WAF1/CIP1 
protein abundances in the pregnant uterus co-exposed to 
DHT and INS. Further, we show that treatment with fluta-
mide effectively reverses DHT + INS-induced deficiencies 
in endometrial receptivity and decidualization and subse-
quently increases the numbers of viable fetuses and restores 
fertility. Likewise, in pregnant mice flutamide treatment 
elicited a marked reversal of testosterone-induced decreases 
in decidualization-related gene expression, and it decreased 
the number of resorbed embryos during implantation [60]. 
Furthermore, in women with PCOS, long-term anti-androgen 
therapy is associated with decreased testosterone levels and 
improved ovulatory function [61]. There is evidence from a 
Swedish nationwide register-based cohort study indicating 
that early treatment with different anti-androgens, including 
flutamide, is correlated with a higher chance of childbirth 
in PCOS patients after spontaneous conception [20]. There-
fore, we reasoned that flutamide regulates PCOS-related poor 
pregnancy outcomes possibly by inhibiting AR-mediated 
reductions in endometrial receptivity and decidualization, 
which are required for implantation during early pregnancy. 
However, the existing literature is contradictory regarding the 
beneficial effects of anti-androgens on decidualization and 
implantation. For instance, during the implantation window 
treatment with hydroxyflutamide, an active metabolite of 
flutamide, suppressed decidualization and delayed implanta-
tion in pregnant and pseudopregnant rats [62]. We speculate 
that the gravid uterus might have a different time frame in 
response to or in the regulation of endometrial receptivity 
and decidualization processes that can change its sensitiv-
ity to treatment with different anti-androgens. In line with 
this speculation, we show that in control pregnant rats flu-
tamide treatment resulted in significantly decreased Lif and 
Il11 mRNA expression, although no negative effect on fetal 
number or fertility was observed. Furthermore, as we demon-
strated in this study, the effectiveness of flutamide on fertility 
is most clearly seen in pregnant rats co-exposed to DHT and 
INS. Because of increased P450 aromatase mRNA expres-
sion in the PCOS endometrium [63], our findings do not rule 
out the possibility that flutamide might affect decidualization 
and implantation through other mechanisms (e.g., through 
interactions with estrogen receptor) in vivo [64], and this 
requires future study.
Emerging evidence suggests that mitochondrial dysfunc-
tion is one of the etiological factors in the pathogenesis of 
PCOS [32]. Recently, we demonstrated that during mid-
gestation the combined exposure to DHT and INS mimics 
the in vivo hyperandrogenism and insulin resistance seen in 
humans and increases mitochondrial abnormalities in the 
gravid uterus and placenta [29–31]. In this study, our find-
ings extend our understanding of the mechanisms governing 
AR-regulated mitochondrial function in the gravid uterus. 
As noted, the presence of flutamide results in increased Nrf1 
mRNA expression and decreased levels of several mitochon-
drial-related proteins (i.e., VDAC, PHB1, and mitochondrial 
respiratory Complexes I and II) along with decreased AR 
and  p21WAF1/CIP1 levels in rats co-exposed to DHT and INS. 
However, flutamide did not restore the mitochondrial struc-
tural defects that result from exposure to DHT and INS. AR 
is predominantly characterized as a nuclear receptor that 
regulates the transcription of target genes [21]. In addition to 
the translocation of AR from the cytoplasm to the nucleus in 
cells [21], the mitochondrial distribution of endogenous AR 
has been demonstrated in human sperm, prostate adenocarci-
noma cells, and skeletal muscle cells [65–67]. Although we 
cannot rule out the possibility that in vivo mitochondrial AR 
alone contributes to PCOS-induced uterine cell dysfunction, 
in vitro studies have shown that flutamide is toxic to mito-
chondria by reducing respiratory Complex I activity [68, 
69]. Therefore, it is likely that the over-activation of nuclear 
AR signaling is responsible for some, if not all, of the gravid 
uterine dysfunction that results in infertility in pregnant rats 
under conditions of hyperandrogenism and insulin resist-
ance. The regulation of AR activation in the nuclear and 
extra-nuclear compartments in uterine cells under physi-
ological conditions and disease states is likely to be more 
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complex than we previously thought, and additional studies 
are needed to determine the mitochondrial AR localization 
and functional relevance in uterine cells (Fig. 7).
For a better understanding of the link between elevated 
endometrial inflammation and PCOS, we recently reported 
the increases in infiltrated endometrial immune cells in non-
pregnant PCOS patients with hyperandrogenism and insulin 
resistance [28, 70]. Similarly, our morphological analysis 
indicates that co-exposure to DHT and INS increases the 
numbers and infiltration of immune cells into the uterine 
endometrium in pregnant rats. Furthermore, this uterine 
pathological phenomenon is also seen in DHT and INS 
co-exposed pregnant rats that receive flutamide treatment 
but fail to complete a normal pregnancy. Our data suggest 
that the inhibition of DHT + INS-induced uterine inflam-
mation is at least partly dependent on decreased AR protein 
and blocked AR signaling. It has long been recognized that 
decidual immune cells such as uterine natural killer (uNK) 
cells and macrophages contribute to appropriate embryo 
implantation and successful pregnancy, and alterations in 
these cell populations may be associated with pregnancy-
related complications [71]. Substantial evidence indicates 
that PCOS patients have aberrant/altered circulating levels of 
immune cells and uNK cell abundance in the uterus during 
the secretory phase of the menstrual cycle [8, 72]. In preg-
nant mice during post-implantation, treatment with testos-
terone propionate decreased the numbers of uNK cells in the 
uterus, and the additional treatment with flutamide restored 
the normal distribution of uNK cells [60]. Although the dif-
ferent types of immune cells, including NK cells and mac-
rophages, in humans and rodents express AR [73], whether 
decidual immune cells also express AR during pregnancy 
remains unclear [22]. Because the endometrial epithelial 
cells and decidual and non-decidual stromal cells are the 
major cell types that express AR [24, 51, 52, 74], we hypoth-
esized that the uterine epithelial and stromal/decidual cells 
modulate immune cell-mediated inflammatory responses 
through paracrine-regulated AR signaling pathways that are 
activated under conditions of hyperandrogenism and insulin 
resistance.
Fig. 7  A schematic represen-
tation illustrating our work-
ing hypothesis regarding the 
regulation and activation of 
gravid uterine AR signaling 
pathways after combined expo-
sure of hyperandrogenism and 
INS resistance. The signaling 
pathway depicted is based on 
the findings of the current study. 
There is evidence that cytosolic 
AR is translocated to and/or 
exists in the mitochondrion in 
several cell types and thus might 
exert effects downstream of the 
hyperandrogenism, thus leading 
to mitochondrial dysfunction. 
Further studies are required 
to determine whether PCOS-
induced uterine cell defects are 
due to the mitochondrial AR 
actions during pregnancy
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Clinical and pre-clinical studies support the notion that 
high levels of maternal androgens (T, A4, and/or DHT) are 
associated with PCOS [25, 26, 29, 30, 42, 43] and early preg-
nant loss [30, 75]. Although direct androgenic actions through 
the AR can only be mediated by T and DHT in tissues/cells 
[21], in vivo and in vitro studies show that androgens that 
operate in a ligand-dependent and cell-specific manner modu-
late uterine cell survival. For instance, in nonpregnant rodents 
in vivo exposure to DHT induces epithelial cell proliferation 
and promotes uterine tissue growth [76, 77], which is medi-
ated by the activation of stromal estrogen receptor α signal-
ing [77, 78]. Despite not always being the case [79], in vitro 
treatment with A4 can increase cell proliferation and decrease 
apoptosis in human endometrial stromal cells [80, 81]. In con-
trast, treatment with T and DHT inhibits cell proliferation in 
human endometrial stromal cells regardless of whether the 
decidualization occurs or not [81–83]. It is currently unknown 
whether endogenous androgens regulate uterine cell prolifera-
tion in pregnant rats; however, chronic exposure of DHT alone 
or in combination with INS from GD 7.5 to GD 14.5 increases 
ferroptosis and decreases apoptosis in the gravid uterus [31]. 
Of note, the trimester-dependent alteration of androgen lev-
els has been observed in humans during normal pregnancy 
[19, 26]. Given that exposure to high doses of DHT results in 
elevated maternal T and A4 levels, which are similar to preg-
nant PCOS patients with hyperandrogenic conditions [25, 26, 
42, 43], it is likely that a crucial regulatory balance between 
the physiological roles and the detrimental effects of maternal 
androgens may determine cell proliferation and cell death in 
the uterus during pregnancy.
In summary, the present findings support the hypothesis that 
the in vivo gestational stage-dependent expression and regula-
tion of uterine AR protein abundance contributes to embryo 
implantation success. The effect of the anti-androgen flutamide 
in the gravid uterus suggests that aberrant AR expression and its 
signaling dysregulates the expression of genes and proteins that 
are involved in endometrial receptivity and decidualization as 
well as in mitochondrial function and that together these result 
in compromised fertility (Fig. 7). While PCOS is one of the most 
frequent causes of infertility in women of reproductive age, it 
has been proposed that the causes for implantation failure in 
PCOS patients might be due to endometrial defects as indicated 
by the dysregulation of the expression of proteins required for 
implantation in the human endometrium [7, 8]. Future studies 
should be directed toward determining whether pregnant PCOS 
patients exhibit similar abnormal expression patterns of AR and 
endometrial receptivity and decidualization-related molecules in 
the gravid endometrium that cause implantation failure. Overall, 
our current results provide new insights into the reproductive 
function of AR in the gravid uterus and provide a mechanistic 
rationale for treating PCOS patients with anti-androgens for pre-
venting pregnancy loss and for improving fertility under condi-
tions of hyperandrogenism and insulin resistance.
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